UNICREDIT BANK/CALL/EVOTEC/14/1/18.06.25 Share Price

Warrant

DE000HD55UP4

Market Closed - BOERSE MUENCHEN 01:16:07 29/06/2024 am IST
0.73 EUR +15.87% Intraday chart for UNICREDIT BANK/CALL/EVOTEC/14/1/18.06.25
Current month+25.86%
1 month+2.82%
Date Price Change
28/24/28 0.73 +15.87%
27/24/27 0.63 -12.50%
26/24/26 0.72 +2.86%
25/24/25 0.7 +22.81%
24/24/24 0.57 +5.56%

Real-time BOERSE MUENCHEN

Last update June 29, 2024 at 01:16 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer UniCredit UniCredit
WKN HD55UP
ISINDE000HD55UP4
Date issued 30/04/2024
Strike 14
Maturity 18/06/2025 (353 Days)
Parity 1 : 1
Emission price 0.98
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.26
Lowest since issue 0.29
Delta0.31x
Omega 3.746
Premium64.29x
Gearing12.05x
Moneyness 0.6411
Difference Strike 5.025
Difference Strike %+35.89%
Spread 0.05
Spread %6.49%
Theoretical value 0.7450
Implied Volatility 54.51 %
Total Loss Probability 84.87 %
Intrinsic value 0.000000
Present value 0.7450
Break even 14.75 €
Theta-0.02x
Vega0.03x
Rho0.02x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.975 EUR
Average target price
20.79 EUR
Spread / Average Target
+131.64%
Consensus